Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review
This article was originally published in The Pink Sheet Daily
Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.
You may also be interested in...
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
Roche’s bitopertin fails in the first two of six Phase III schizophrenia trials to report, raising questions about prospects for more diversity outside the company’s core strength in oncology.
Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now, the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.